Premedication with fast-acting oxycodone hydrochloride hydrate effectively reduced oxaliplatin-induced severe vascular pain

Nagao, Sayaka; Furihata, Makoto; Fukagawa, Kazushi; Furihata, Tadashi; Matsuhashi, Yuki; Wada, T.

doi:10.1016/j.jiac.2017.02.006

Cited by 6 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Co-infusion of dexamethasone 7 , prewarming peripheral blood vessels 16 , premedication with oxycodone, and altering the dose rate have all been investigated as countermeasures against oxaliplatin-induced vascular pain 6 . The effects of many of these countermeasures on vascular pain were assessed by VAS.…”

Section: Discussionmentioning

confidence: 99%

“…However, CAPOX therapy with peripheral venous administration of oxaliplatin has been reported to cause vascular pain 3,4 , and the low pH and hyperosmolarity of the solution, as well as small vein size and rapid infusion rate, are known to be associated with infusion phlebitis 5 . The development of vascular pain and phlebitis following intravenous infusion of antineoplastic agents subsequently increases the risk of discontinuation of chemotherapy 6 . Co-infusion of dexamethasone 4,7,8 , prewarming the peripheral blood vessels 9 , premedication with oxycodone 6 , and changing the dose rate have all been investigated as ways of reducing oxaliplatin-induced vascular pain.…”

Section: Introductionmentioning

confidence: 99%

“…The development of vascular pain and phlebitis following intravenous infusion of antineoplastic agents subsequently increases the risk of discontinuation of chemotherapy 6 . Co-infusion of dexamethasone 4,7,8 , prewarming the peripheral blood vessels 9 , premedication with oxycodone 6 , and changing the dose rate have all been investigated as ways of reducing oxaliplatin-induced vascular pain. To determine which techniques are most effective, it is necessary to objectively evaluate vascular pain.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of vascular pain in patients with colorectal cancer receiving peripheral venous chemotherapy with or without oxaliplatin

Matsuoka

Yoshida

Aisu

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Oxaliplatin is a key chemotherapy drug in patients with colorectal cancer. Administration of oxaliplatin via a peripheral vein often causes vascular pain. However, no studies have evaluated vascular pain in patients with colorectal cancer in relation to peripheral venous administration of chemotherapy with or without oxaliplatin. We evaluated oxaliplatin-induced vascular pain using subjective and objective methods. We determined if oxaliplatin induced vascular pain in patients with colorectal cancer using a Visual Analog Scale (VAS) and a PainVision PS-2100 device. We compared VAS score between chemotherapy regimens with or without oxaliplatin, and between genders. We also examined the correlations of VAS score with pain intensity examined by the PainVision PS-2100, and with age and vessel diameter. A total of 98 patients with colorectal cancer were enrolled in this study, including 78 patients who received oxaliplatin via peripheral venous administration and 20 who received chemotherapy without oxaliplatin. The median VAS scores in patients with and without oxaliplatin were 36.5 (interquartile range 9.0–60.0) and 0 (0–4.0), respectively (P < 0.001), and the median pain intensities according to PainVision were 43.5 (14.3–98) and 36.5 (9.3–58.5), respectively (P < 0.001). There was a positive correlation between VAS and pain intensity (r = 0.584), but no correlation between VAS score and age (r = −0.174) or vessel diameter (r = −0.107). Peripheral venous administration of oxaliplatin induced vascular pain, measured both subjectively and objectively, in patients with colorectal cancer, regardless of vessel diameter.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of vascular pain in patients with colorectal cancer receiving peripheral venous chemotherapy with or without oxaliplatin

Matsuoka

Yoshida

Aisu

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Of note, it applies analgesic and sedative effects in a dose-dependent manner. Besides, dexmedetomidine also suppresses systemic inflammatory responses in patients with sepsis and reduces serum TNF-α, IL-6, and IL-8 levels (Nagao et al 2017). Separately, oxycodone is currently the only opioid amboceptor agonist available in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Effects of dexmedetomidine combined with oxycodone on sedation effect, perioperative inflammatory response and immunity

Wang¹,

Zhang²,

Wu³

et al. 2020

All Life

View full text Add to dashboard Cite

Dexmedetomidine is a novel, highly selective α2 adrenoceptor agonist, whereas oxycodone serves as a μand k-amboceptor agonist. To analyze the effects of dexmedetomidine combined with oxycodone in locally anesthetized patients undergoing transforaminal endoscopic resection of nucleus pulposus. 112 patients were evenly randomized into oxycodone group (OG), dexmedetomidine group (DG), oxycodone-dexmedetomidine combination group (ODG), and control group (CG). No significant difference among the four groups in terms of baseline information, recovery time, or atropine was found (p > 0.05). The mean arterial pressures (MAPs) and heart rates (HRs) in ODG reduced from the injection point and were dramatically lower over those in CG, and visual analog scale (VAS) scores in ODG at 1, 2, and 6 h following surgery were lower over those in other groups (p < 0.05). The combination of dexmedetomidine with oxycodone in the local anesthesia during analgesia and sedation of patients undergoing transforaminal endoscopic resection of the nucleus pulposus manifested tangible effects. Specifically, such improved perioperative inflammatory responses and controlled cellular immunity without promoting the onset of adverse reactions.

show abstract

“…In this study, however, we assessed only whether or not the treatments altered the incidence of vascular pain, as the available data did not allow us to determine whether they were effective in reducing the severity of pain. Nagao et al have reported that pretreatment with fast-acting oxycodone reduced vascular pain induced by oxaliplatin via a peripheral vein [ 15 ]. However, in our study, treatment with analgesics including opioids and/or NSAIDs did not reduce the incidence of vascular pain (Fig.…”

Section: Discussionmentioning

confidence: 99%

Risk factors for oxaliplatin-induced vascular pain in patients with colorectal cancer and comparison of the efficacy of preventive methods

Suga

Ikeda

Maeda

et al. 2018

J Pharm Health Care Sci

View full text Add to dashboard Cite

BackgroundVascular pain is a common adverse drug reaction in colorectal cancer patients receiving peripheral venous administration of oxaliplatin. The aim of this work was to identify risk factors for vascular pain, and to examine whether currently used treatments reduce its incidence.MethodsWe conducted a multicenter retrospective study in Japanese colorectal cancer patients receiving peripheral venous administration of oxaliplatin. The effects of various treatments (administration of analgesics, addition of dexamethasone to the infusion solution for pH adjustment, dilution of the infusion solution, or use of hot gel for warming the injection site) on the incidence of vascular pain were assessed. Risk factors for vascular pain were identified by multiple logistic regression analysis.ResultsOne hundred and ninety patients who had received an oxaliplatin-containing regimen via a peripheral venous route were analyzed. None of the preventive methods examined significantly reduced the incidence of vascular pain. BMI (BMI < 22), clinical stage (I-III) and oxaliplatin dosage (130 mg/m2 versus dose reduction) were identified as independent risk factors for development of vascular pain. The incidence of oxaliplatin-induced vascular pain was significantly higher in patients who had two or more risk factors.ConclusionsBMI, clinical stage and oxaliplatin dosage were identified as independent predictive markers for oxaliplatin-induced vascular pain. Existing treatments for vascular pain are not effective in reducing its incidence.

show abstract

Premedication with fast-acting oxycodone hydrochloride hydrate effectively reduced oxaliplatin-induced severe vascular pain

Cited by 6 publications

References 11 publications

Evaluation of vascular pain in patients with colorectal cancer receiving peripheral venous chemotherapy with or without oxaliplatin

Evaluation of vascular pain in patients with colorectal cancer receiving peripheral venous chemotherapy with or without oxaliplatin

Effects of dexmedetomidine combined with oxycodone on sedation effect, perioperative inflammatory response and immunity

Risk factors for oxaliplatin-induced vascular pain in patients with colorectal cancer and comparison of the efficacy of preventive methods

Contact Info

Product

Resources

About